Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II mogamulizumab plus lenalidomide in relapsed/refractory CCR4-positive aggressive ATL
jRCTs071180079Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab and lenalidomide in adult T-cell leukemia-lymphoma (ATLL), sponsored by Bristol Myers Squibb. Primary endpoints: Phase I recommended dose and Phase II overall response rate. Started Aug 2020; status: completed.
02
Drugs
mogamulizumablenalidomide
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCTs071180079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180079.